Despite the fact that the pharmacy retains the very significant financial responsibility for drug spend and concentrates on trying to limit this in a number of ways, in comparison, pharmacy spends very little time or effort or has very little involvement in ensuring payment for those very expensive high investment drugs or even in designing and implementing payment strategy. The CDM is at the core of this, but unfortunately, often is bloated, cumbersome, outdated and missing critical elements. Additionally, the session provides suggestions and tools for assessing current practice and making needed changes. It’s not only about money but about assuring data accuracy. The series will cover the entire reimbursement cycle including inpatient as well as retail and outpatient reimbursement rules and best practices.